In a combination therapy model, NanoAlb‐proDOX synergistically elevated the efficacy of immune checkpoint blockade with enhanced infiltration of cytotoxic CD8+ T cells into the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.